North America Infusion Devices Market Size and Forecast 2021 - 2031, Regional Share, Trend and Growth Opportunity Analysis Report Coverage: By Product Type, Application, End User and Country

The North America infusion devices market size is projected to reach US$ 9.11 billion by 2031 from US$ 5.49 billion in 2023. The market is expected to register a CAGR of 6.5% during 2023-2031.

According to the US Census Bureau, the number of Americans aged 65 and above is expected to rise from 58 million in 2022 to 82 million by 2050, which is a 47% increase. Additionally, the share of the total population for the 65-and-older age group is projected to rise from 17% to 23%. According to Statistics Canada, in 2022, almost ~18.8% of Canadians were aged 65 years. Almost 20% of the Canadian population is aged 65 years and above. Furthermore, population projections suggest that 21% to 29% of Canadians could be aged 65 or above by 2068.

A few key benefits of infusion therapy administered in senior populations are listed below.

• Rehydration and electrolyte balance: Dehydration can be a higher risk for seniors due to factors such as decreased thirst, certain medications, and changes in kidney function. IV fluids can help seniors maintain the necessary hydration and electrolyte levels for overall health.
• Nutrition support and improvement: Aging makes it harder for human bodies to consume the right nutrients, increasing the risk of chronic illnesses. Infusion therapy provides a direct way for seniors to get essential minerals, vitamins, and amino acids efficiently.
• Immune function reinforcement: Immune systems of elderly people may need extra support, as they are more vulnerable to infections. Infusion therapy can deliver immune-boosting nutrients such as vitamin C, zinc, and glutathione directly to the body.
• Pain management: Many seniors deal with chronic pain daily, affecting their quality of life. Infusion therapy can quickly and effectively manage pain by delivering medication directly into the bloodstream, providing relief and reducing inflammation.

Thus, the increasing geriatric population drives the demand for infusion devices across North America.

Strategic Initiatives by Market Players

Various market players focus on strategic developments such as product launches, mergers, acquisitions, and collaborations to develop advanced products that help ease the treatment of chronic disorders such as diabetes, cancer, chronic pain among others. Following are a few recent developments in the North America infusion devices market.

• In April 2024, Mackenzie Health launched a technology in Canada that allows for two-way information flow between an intravenous (IV) medication pump and a patient’s electronic medical record. The technology, known as BD Alaris EMR Interoperability, eliminates the need for healthcare professionals to manually program pumps. It sends infusion safety information back to Epic EMR, reducing the risk of administration errors and providing an accurate infusion record in the EMR.
• In November 2022, Medtronic plc announced the launch of Medtronic Extended infusion set in the US. It is the first and only infusion set labeled for up to seven-day wear. An infusion set is tubing that delivers insulin from an insulin pump to the body and usually needs to be changed every two to three days.
• In May 2022, Fresenius Kabi acquired Ivenix and its advanced infusion pump technology, expanding its portfolio of advanced infusion pumps and solutions for healthcare professionals to address healthcare needs across the care continuum. Fresenius Kabi also announced that it has rapidly expanded its infusion therapy portfolio in the US, obtaining FDA approvals for multiple IV solutions in anticipation of qualifying its North Carolina manufacturing site to supply the US customers with IV solutions.
• In March 2022, Fresenius Kabi received 510(k) regulatory clearance from the FDA for its wireless Agilia Connect Infusion System. The system includes the Agilia Volumetric Pump and the Agilia Syringe Pump with Vigilant Software Suite-Vigilant Master Med technology. Both pumps are the first to be cleared following TIR101 standards, which were developed by the Association for the Advancement of Medical Instrumentation (AAMI) in 2021.

An upsurge in the number of product approvals, launches, and strategic collaborations is likely to create lucrative opportunities for the infusion devices market in the future.

End User-Based Insights

Based on end user, the North America infusion devices market is divided into hospitals and specialty clinics, homecare settings, ambulatory surgical centers, and others. The hospitals and specialty clinics segment dominated the market in 2023. The homecare settings segment is anticipated to register the highest CAGR during 2023-2031. Hospitals and clinics are primary contact points for patients to get their diagnosis done and opt for treatment options and alternatives. Available infrastructure in hospitals and clinics can provide high-quality care for patients suffering from any disease condition as they have access to advanced medical devices. The hospitals and clinics segment is projected to hold a considerable market share as a majority of patients in emerging nations and developed countries prefer visiting hospitals for health-related problems.

Infusion pumps are being used on a large scale in hospitals and clinics, owing to the additional benefits offered by the pumps such as precision, accuracy, and ease of use. The pumps can be used for applications such as chemotherapy, pain management, and diabetes management, which are the major reasons for patients being admitted for longer and shorter duration.

WellSpan Health and CareFusion, a BD company, jointly announced the implementation of the Alaris System across all four WellSpan hospitals. WellSpan York Hospital is the first hospital to go live with new infusion devices and bi-directional interoperability between the electronic health record and infusion device.

Hence, the benefits and the multiple applications of infusion pumps fuel the North America infusion devices market growth for the hospitals and clinics segment.

• By application, the market is segmented into diabetes, oncology, pain management, hematology, pediatrics, gastroenterology, and others. The diabetes segment held the largest share of the market in 2023, and it is projected to register the highest CAGR in the market during 2023-2031.
• Based on end user, the North America infusion devices market is divided into hospitals and specialty clinics, homecare settings, ambulatory surgical centers, and others. The hospitals and specialty clinics segment dominated the market in 2023. The homecare settings segment is anticipated to register the highest CAGR during 2023-2031.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America infusion devices market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the North America infusion devices market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.